Trade school ‘RioTECH' opens in Rio Rancho
Story continues below
New Mexico Insiders: What goes on at Kirtland Air Force Base?
Film: Balloon Fiesta showcased in new Hallmark movie
Crime: Alleged Venezuelan gang member arrested at Doña County judge's home
Trending: NM Supreme Court rules that 911 dispatchers are liable in emergency call lawsuits
'Today not only marks a celebration in progress in partnership but a powerful step forward for our community, students, and the future of education and workforce development here in New Mexico,' said Dr. Kristopher Johnson, Principal at RioTECH.
The $55 million school in Rio Rancho has been in the works since 2017, a partnership with Central New Mexico Community College. Some teaching is already happening there, but by fall, 150 high school students will take part in regular courses taught by CNM instructors. They'll also enroll more than 100 adult trade students.
'As they graduate, they're going to have to learn to work with all different walks of life and people from everywhere, so it's important to start them now and working with the industry that they're going into,' said Johnson.
Saying that 93% of businesses in New Mexico are Career Technical Education-related, the Rio Rancho Chamber said the school fills a big need in the state's workforce.
'Right now, what we have is a shortage of our workforce, we have an aging workforce. This allows these students to gain those skills that are necessary to move forward,' said Jerry Schalow, President and CEO of Rio Rancho Regional Chamber of Commerce.
'It's more interactive and you're actually doing the stuff hands-on,' said Josiah Lopez, future RioTECH student.
'This place will be better because it has more resources for me to utilize and there's more people that can help me out to achieve my goals,' said Jasmine Lamb, future RioTECH student.
RioTECH is expected to finish construction and be fully open by the fall. They're already making a waiting list, and more information can be found on their website.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
19 hours ago
- Forbes
Augusta Precious Metals Review 2025
Augusta Precious Metals is better suited if you're retired or nearing retirement and looking to diversify your retirement portfolio with precious metals exposure. In general, if you have a longer time horizon, you're better off with the stock market or long-term growth investments that can survive downturns over time. While having a small position in precious metals may dampen portfolio volatility in the short-run, the tradeoff between slightly dampened volatility and the lost long-term return is certainly not a prudent one, particularly for Generation-Z [or] millennials with long investing time horizons. – Robert Johnson, a chartered financial analyst, chairman and CEO of Economic Index Associates and professor of finance at the Heider College of Business at Creighton University Augusta requires a high initial investment of $50,000. Financial advisors typically recommend allocating no more than 5% to 10% of your overall portfolio to precious metals. That means, ideally, you need a total retirement portfolio of $500,000 to $1 million to justify that minimum. The idea behind investing in a gold IRA, such as one offered by Augusta Precious Metals, is that it works as an inflationary hedge. For example, if you have your money in cash, the cost of inflation erodes your purchasing power. The strategy of using a gold IRA is that the underlying assets appreciate in either a tax-deferred or tax-free Roth account. Concierge Customer Service Some of the perks of choosing Augusta are its transparent pricing and concierge-like customer service. It's a great option for those who'd prefer hand-holding when it comes to investment products. With Augusta, you'll be assigned a dedicated customer service agent throughout the account setup and management process. The downside is you can't set up or apply for an account online. If you prefer to go to a website without having to contact a person over the phone for transactions, you're out of luck. The website chat feature funnels customers into a customer service phone call.
Chicago Tribune
a day ago
- Chicago Tribune
Editorial: So is City Hall hiking property taxes or ruling them out?
There's going to be a Chicago property tax increase. Fooled ya'. Might the corporate head tax be revived instead? Yes. No. Wait! Chicago will impose a 'progressive revenue' solution to be named later. Say what? Mayor Brandon Johnson and the city's chief financial officer, Jill Jaworski, really didn't seem to have their stories straight last week as they sought to prepare Chicagoans for the difficult budget debate to come in the fall. First, Jaworski, speaking July 22 at a Bloomberg News event, said 'it was likely' the mayor's budget would include a proposed property tax increase alongside budget cuts in order to close an estimated $1.1 billion deficit for 2026. Asked about Jaworski's comments, Johnson at first didn't rule out a such an increase and, as per usual, blamed his predecessors for Chicago's budgetary woes. But on Thursday, two days after Jaworski's remarks, the mayor was singing a different tune. 'I will not be proposing a property tax increase in my budget,' he said, seemingly categorically. Seemingly. He said, as he has done many times in the past, that he would 'work hard to find progressive revenue' to help balance the city's books. Johnson didn't specify what progressive tax policies he would propose other than to say, 'the ultimate goal is to challenge those with means in this city, and quite frankly in this state, to pay their fair share.' Stop us if you've heard this one before. As Johnson prepared to take office following his surprise election win in 2023, progressive groups supporting his candidacy floated hundreds of millions in new taxes, with ideas ranging from a tax on financial trades to the reinstitution of the per-employee head tax on businesses and many others. Most of those new taxes would have needed, and would still need, state approval, and Gov. JB Pritzker along with numerous lawmakers quickly shot down the Johnson tax-bonanza agenda. For good reason, too. A state with such lagging economic performance as Illinois can't afford to be driving away more wealthy and middle-class people and businesses. Then Chicago voters themselves in 2024 rejected a Johnson-backed referendum to dramatically hike the tax on sales of property above $1 million, which likely would have raised apartment rents and further constricted our wheezing commercial real estate industry. So here we are. We're well past the halfway point of Johnson's term, and he's still knocking at the 'progressive taxation' door. We'll reserve judgment until we see precisely what the mayor has in mind. Maybe he and his team have devised some new plan not yet proposed (and rejected) that's worthy of consideration. We won't hold our breath. But it doesn't instill confidence that the mayor himself had to walk back his top financial aide's comments on property taxes a few days after she made them. Perhaps Jaworski was just floating a trial balloon, and Johnson got an earful in the two days between her remarks and when he effectively told reporters she'd spoken out of turn. Property tax hikes right now are a political third rail. Johnson found that out in the most humiliating way possible last year when the City Council unanimously rejected his budget, including a proposed $300 million property tax increase that broke one of Johnson's most noteworthy campaign promises. Attempts to win council support for a smaller hike went nowhere as well, and Johnson and aldermen patched together a budget at the eleventh hour with a hodgepodge of fee increases, business taxes and fines. So is a property tax hike in what is shaping up to be a more brutal budget year than last year's high-wire act really off the table? We don't know. But forgive us if we're skeptical that Johnson's cleanup of Jaworski's property-tax bombshell will be the last word on the subject.
Business Insider
3 days ago
- Business Insider
How Johnson & Johnson Stock (JNJ) Discovered a New Lease of Life
Biopharma giant Johnson & Johnson's (JNJ) stock hit new highs this year after reporting its Q2 results on July 16th, giving the market a clear signal that it's reigniting growth with practically flawless numbers—a potential turning point for the second half of the year. The upwardly revised guidance and expectations for strong margin expansion, despite lingering litigation concerns, have brought fresh optimism to the stock and appeased shareholders clamoring for added value. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. While the stock isn't as discounted as it was earlier this year, valuations still look reasonable. Given JNJ's strong compounding potential and this renewed bullish momentum, I see it as a Buy. How J&J's Strong Quarter Sets the Stage for Growth Johnson & Johnson stock has been rangebound for years, weighed down by a mix of factors, including a massive wave of lawsuits claiming its talc-based baby powder caused cancer due to asbestos contamination, as well as expiring drug patents, such as its blockbuster Stelara losing exclusivity. Last but not least is sluggish growth and an eroded safe-haven reputation, since legacy consumer brands like Tylenol, Listerine, and Band-Aid have low growth and face margin pressure from cheap competition. According to TipRanks data, JNJ has underperformed the S&P quite considerably since 2024. Johnson & Johnson's latest Q2 earnings may mark a true inflection point toward more consistent alpha generation. The company delivered exactly what it needed— beating both earnings and revenue expectations —while issuing a notable upward revision to guidance: an additional $2 billion in forecasted sales and $0.25 more in projected EPS. For a pharma giant like J&J, that's a clear signal of renewed momentum following a prolonged period of litigation-related overhang. Management also reaffirmed its full-year outlook for a 300-basis-point improvement in operating margin, raising it from approximately 25.4% to 28.4%. Notably, the quarter wasn't just about numbers. J&J reported compelling 5-year trial results for its multiple myeloma immunotherapy—an encouraging sign in the fight against a challenging cancer. The company also set an ambitious goal: to become the global leader in oncology by 2030, with a target of over $50 billion in cancer drug sales. With a potential $5 billion peak opportunity in bladder cancer and a strong pipeline aimed at offsetting losses from aging blockbusters, J&J is signaling that real innovation is back at the forefront. Breaking Free from the Margin Squeeze While markets often reward margin expansion, Johnson & Johnson looks especially well-positioned to benefit going forward. In addition to raising full-year earnings guidance, the company also delivered positive updates on cost pressures— halving its expected tariff impact from $400 million to $200 million and projecting a $1.1 billion tailwind from favorable currency shifts as the U.S. dollar weakens. The reduced tariff burden is primarily attributed to the MedTech division, which is more exposed to global supply chains and international manufacturing than the pharmaceutical segment. That's a clear tailwind for margins and future profitability. It's also important to note how strategic portfolio decisions have helped set the stage for this improvement. The 2023 spin-off of Kenvue—essentially the entire Consumer Health business—removed a lower-margin segment from the mix, sharpening J&J's focus on higher-margin areas. This move highlights the company's commitment not only to defending margins but also to actively growing them. In today's market, stability alone isn't enough—investors are looking for real margin expansion, and Johnson & Johnson seems intent on delivering. Analysts have responded by raising their EPS estimates for 2025 and 2026 by about 2% compared to before Q2 earnings. They now expect full-year EPS in 2025 to hit $10.86 —an 8.7% increase from last year—and to reach $11.34 in 2026, representing an annual growth rate of 4.4%. Reasonable Valuation with Growth on the Horizon Johnson & Johnson is a vast, stable, and diversified company, so its valuation tends to reflect relative stability rather than wild growth. Looking at its forward earnings multiple, currently around 15.5x, it's basically in line with the five-year average. This is well above the lows seen earlier this year, when it traded as low as 11x forward earnings in January. To me, this suggests the valuation isn't necessarily cheap, but it's reasonable. Comparing J&J's current earnings multiples over the last twelve months to its main peers, the 17.5x P/E ratio sits close to the sector average. Except for Merck & Co. (MRK), J&J is actually one of the more discounted names in the group. Finally, with a dividend yield of almost 3%, the stock no longer appears exuberant, and the yield isn't particularly compelling—especially when compared to the 10-year U.S. Treasury yield. However, J&J's payout ratio is typically safe, at around 50% of earnings, which helps build shareholder trust. Additionally, the market is now anticipating a more positive growth trajectory following the recent upward revisions to guidance, both last quarter and earlier this year. Is JNJ Stock a Buy, Hold, or Sell? Wall Street sentiment on Johnson & Johnson remains mixed, with more caution than conviction among analysts. Of the 19 analysts who have issued ratings over the past three months, nine are bullish, while the remaining ten are neutral. The average price target stands at $176.35, suggesting a modest upside of approximately 4.3% from the current share price. Johnson & Johnson Positioned for Consistent Alpha Generation Johnson & Johnson has, in my view, successfully restored market confidence in both its innovation pipeline and cost discipline—key pillars that could drive renewed growth and support reliable shareholder returns for decades to come. For long-term investors, initiating a position now is essentially a bet on a proven dividend combined with steady capital appreciation—an attractive formula that has historically outperformed the broader market. While the stock appears fairly valued at current levels, it offers compelling potential for compounding returns and consistent alpha generation in the years ahead.
